Mammoth Biosciences has secured a subcontract with MRIGlobal to develop CRISPR-based diagnostics and bio- surveillance technologies. The program aims to create scalable and rapidly adaptable CRISPR-based diagnos- tics platforms to protect against future pandemics and biological national security threats, with the idea that rapid and affordable diagnostics and CRISPR are part of a future solution to these problems. The contract goals are to develop two devices: a handheld, disposable point-of-need (PON) device capable of detecting 10 pathogens at once, as well as a lab-based massively multiplexed detection (MMD) platform capable of screening clinical and environmental samples for more than 1,000 targets simultaneously.
Enter our Sweepstakes now for your chance to win the following prizes:
Just answer the following quick question for your chance to win:
Entries are limited to one entry per person in any active sweepstakes.
Thank you for your entry.